MiT family translocation renal cell carcinoma is a rare and aggressive subgroup of renal cell carcinoma (RCC), a type of kidney cancer. People with translocation RCC have high levels of a gene called c-MET. Translation RCC dos not respond well to treatment with targeted therapies or immunotherapies. However, the effectiveness of cabozantinib in these patients is unclear.

This real-world study included 52 patients with metastatic translocation RCC. Eleven (21.2%) patients were given cabozantinib as a first-line treatment, 15 (28.8%) as a second-line treatment, and 26 (50%) as a third-line or beyond treatment. Nearly a fifth of patients responded to treatment, including 2 complete responses and 7 partial responses. Stable disease was achieved in half of the patients.

The patients were followed-up for around 2 years, and the average time to when the treatment stopped working and the cancer started growing again was 6.8 months. Average overall survival time was 18.3 months.

This real-world study shows that cabozantinib is effective for people with translocation RCC, and has better outcomes than other targeted therapies snd immunotherapies that have been tested in these patients.

Read more in UroToday here